Pre‐existing, treatment‐specific resistance‐associated substitutions in hepatitis C virus genotype 1 and 3 and viral RNA titers during treatment with direct‐acting antivirals
APMIS · 2023
DOI: 10.1111/apm.13335 ↗Kurz gefasst
Fachartikel in der Zeitschrift APMIS, 2023. Verfasst von Christina Sølund und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Hepatitis C. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Roskilde University, The A.P. Møller Foundation for the Advancement of Medical Science, The Capital Region of Denmark's Research Foundation.
Abstract (Originalsprache)
The introduction of direct‐acting antiviral (DAA) treatment of hepatitis C virus (HCV) infected patients has greatly increased treatment success rates. However, viral response kinetics to DAA treatment may depend on pre‐existing resistance‐associated substitutions (RASs) in HCV. The aim of this study was to describe how pre‐existing RASs affect DAA treatment‐induced reduction in HCV RNA titers in HCV genotypes 1‐ and 3‐infected individuals. Patients with HCV genotype 1 infection (N = 31) treated with either sofosbuvir/ledipasvir/ribavirin or paritaprevir/ombitasvir/ritonavir/dasabuvir/ribavirin and HCV genotype 3‐infected patients (N = 16) treated with either sofosbuvir/daclatasvir/ribavirin or sofosbuvir/ribavirin were analyzed. HCV RNA levels were determined at baseline and frequently during treatment, and RAS profiles were obtained by deep sequencing at baseline. In total, 33/47 (70.2%) of the patients had baseline RASs. However, treatment‐specific RASs were detected at baseline only in 12.9% and 18.8% of HCV genotypes 1‐ and 3‐infected patients, respectively. In genotype 1‐infected individuals, reduction in HCV RNA titer during the first week of treatment was not affected by evidence of either treatment‐specific RASs or cirrhosis or treatment regimen. In genotype 3‐infected individuals receiving sofosbuvir/daclatasvir/ribavirin, the presence of daclatasvir‐specific NS5A RASs at baseline correlated with a reduced decline of HCV RNA in the first treatment week. For both genotypes 1‐ and 3‐infected individuals, cirrhosis but not treatment‐specific RAS were associated with the time of clearance of HCV RNA. It is, however, important to note that this study involves DAA regimens that were used only during the original introduction of interferon‐free DAA‐based treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark.
- Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark.
- CO-HEP, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Department of Clinical Microbiology, Copenhagen University Hospital, Hvidovre, Denmark.
- Department of Science and Environment, Roskilde University, Roskilde, Denmark.
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Håvard Jenssen, Kristian Schønning, Jens Bukh
Förderung
- Roskilde University
- The A.P. Møller Foundation for the Advancement of Medical Science
- The Capital Region of Denmark's Research Foundation
- The Innovation Fund Denmark
- The Novo Nordisk Foundation
- The Independent Research Fund Denmark
Zitieren
APA
Sølund, C., Pedersen, M. S., Fahnøe, U., Filskov, J., Jenssen, H., Weis, N., Schønning, K., & Bukh, J. (2023). Pre‐existing, treatment‐specific resistance‐associated substitutions in hepatitis C virus genotype 1 and 3 and viral RNA titers during treatment with direct‐acting antivirals. APMIS. https://doi.org/10.1111/apm.13335
Vancouver
Sølund C, Pedersen MS, Fahnøe U, Filskov J, Jenssen H, Weis N, et al. Pre‐existing, treatment‐specific resistance‐associated substitutions in hepatitis C virus genotype 1 and 3 and viral RNA titers during treatment with direct‐acting antivirals. APMIS. 2023. doi:10.1111/apm.13335
BibTeX
@article{Slund2023,
author = {Sølund, Christina and Pedersen, Martin S and Fahnøe, Ulrik and Filskov, Jonathan and Jenssen, Håvard and Weis, Nina and Schønning, Kristian and Bukh, Jens},
title = {Pre‐existing, treatment‐specific resistance‐associated substitutions in hepatitis C virus genotype 1 and 3 and viral RNA titers during treatment with direct‐acting antivirals},
journal = {APMIS},
year = {2023},
doi = {10.1111/apm.13335}
}
EUVIMED